Alnylam Pharmaceuticals Q4 2025 Earnings Preview: Recent Insider Activity with $ALNY

Alnylam Pharmaceuticals is set to release its fourth-quarter earnings data on January 12th after the market closes. Analysts are predicting revenue of $1,196,699,190 and earnings of $1.25 per share. Quiver Quantitative provides a platform where you can track data on insider trading, hedge fund activity, congressional trading, and more related to Alnylam Pharmaceuticals, known by the ticker symbol $ALNY.

Insiders at Alnylam Pharmaceuticals have been actively involved in trading the company’s stock over the past six months. There have been a total of 176 trades, with all being sales and no purchases recorded during this period. Notable sales include Yvonne Greenstreet, the Chief Executive Officer, who sold 41,553 shares totaling approximately $18,810,433. Dennis A Ausiello made 11 sales, selling 31,448 shares worth $13,729,535. Colleen F Reitan conducted 16 sales, selling 18,000 shares valued at $8,416,729. Kevin Joseph Fitzgerald, the CSO & EVP, Head of Research, sold 15,965 shares in 31 transactions amounting to $7,220,199. Michael W Bonney sold 11,250 shares for an estimated $5,062,500. Pushkal Garg, the EVP Chief R&D, sold 8,810 shares, generating $3,991,807. Tolga Tanguler, the EVP, Chief Commercial Officer, conducted 26 sales, selling 6,275 shares amounting to $2,825,534. Jeffrey V. Poulton, the EVP, Chief Financial Officer, sold 6,095 shares in 20 transactions totaling $2,758,010. To keep track of insider transactions, you can refer to Quiver Quantitative’s insider trading dashboard.

In the third quarter of 2025, Alnylam Pharmaceuticals reported revenues of $1.2B, marking a significant 149.35% increase from the same period the previous year. Tracking the financials of Alnylam Pharmaceuticals can be done through Quiver Quantitative’s ALNY stock page.

A total of 480 institutional investors have added shares of Alnylam Pharmaceuticals to their portfolio, while 283 have decreased their positions in the most recent quarter. Some notable moves include Regeneron Pharmaceuticals, Inc., which removed 3,052,142 shares (-68.7%) from their holdings in Q3 2025, estimated at $1,391,776,752. JPMorgan Chase & Co added 2,481,762 shares (+120.4%) to their portfolio in Q3 2025, amounting to $1,131,683,472. T. Rowe Price Investment Management, Inc. removed 2,107,295 shares (-49.2%) in Q3 2025, valued at $960,926,520. For further details on hedge funds’ stock portfolios, you can visit Quiver Quantitative’s institutional holdings dashboard.

The expert opinions from Wall Street analysts suggest a positive outlook for Alnylam Pharmaceuticals. Over the recent months, there have been 16 firms issuing buy ratings on the stock and no sell ratings. Analysts’ ratings are a key indicator of the stock’s performance and sentiment within the market.

Multiple analysts have provided price targets for Alnylam Pharmaceuticals, with a median target of $490.0 based on 25 analysts’ projections in the last six months. Individual target prices have been set by analysts such as Danielle Brill, Mani Foroohar, Paul Matteis, Derek Archila, Gena Wang, Edward Tenthoff, and Maury Raycroft. These targets are pivotal in understanding the potential future growth of the company’s stock.

This article does not serve as financial advice and aims to provide details on Alnylam Pharmaceuticals’ upcoming earnings, insider trading activities, hedge fund moves, analyst ratings, and price targets. For further information, readers are advised to refer to Quiver Quantitative’s disclaimers for more accurate insights on the company.